Forecast

The analysts' average price target is +10,30€ (+37,52%). The median is +10,30€ (+37,52%).

Buy	10
Hold	1
Sell	0

News Go to news feed

Xeris Biopharma beats Q2 revenue forecasts, misses EPS due to one-time GAAP charge

Xeris Biopharma reported Q2/2026 revenue of $92.1 million, topping consensus, but reported EPS of -$0.18 versus an expected $0.01 due to a one-time, non‑cash GAAP charge from the revaluation of convertible notes. Net product revenue growth was driven mainly by RECORLEV (net $56.8M, +81% YoY) and a recovery at Gvoke; adjusted EBITDA rose to $19.3M. Xeris raised its full-year revenue guidance to $385–390M but forecast higher SG&A and R&D expenses, including spending to prepare Phase III trials of XP-8121. In July the company redeemed $34M of convertible notes, lowering interest costs; however, investors reacted cautiously premarket to the earnings miss. » More on de.investing.com
Xeris: CEO John Shannon will also serve as chairman of the board

The board of directors of Xeris appointed CEO John Shannon effective July 1, 2026, as chairman of the board; Marla Persky remains the lead independent director. At the same time, Dr. Nerissa Kreher was appointed to the board, which is thereby expanded to eight members. Under Shannon’s leadership, revenue in the last twelve months rose 41% to $315 million, the stock delivered a one‑year return of 66%, and market capitalization is about $1.34 billion. » More on de.investing.com
US Patent Office grants Xeris patent protection for Keveyis through 2039

The US Patent and Trademark Office has issued a notice of allowance for Xeris’ Keveyis patent application (No. 17/151,405); after completion of administrative steps, the patent is expected to protect Keveyis through 2039. Xeris plans to submit the patent to the FDA for listing in the Orange Book. The company recently reported revenue growth of 41% to $315 million and a gross margin of 86%, is profitable according to analysis, and shows analysts’ expectations for further earnings growth. » More on de.investing.com

Financials

In the last quarter, Xeris Pharmaceuticals had revenue of 80.70m€ and net profit of −27.25m€

(EUR)	Jun 2026	YoY
Revenue	+80.70m	32,96%
Gross profit	+69.74m	44,38%
Net profit	−27.25m	1.565,96%
EBITDA	−18.51m	353,80%

Fundamentals

Metric	Value
Market capitalization	+1.29b€
Number of shares	172.64m
52-week high/low	+8,65€ - +4,51€
Dividends	No
Beta	0,85
P/E ratio	−89,39
PEG ratio	+0,01
P/B ratio	−154,11
P/S ratio	+4,47

Company profile

Xeris Biopharma Holdings, Inc. ist ein biopharmazeutisches Unternehmen, das sich mit der Entwicklung und Vermarktung von Therapien für Patientengruppen in der Endokrinologie, Neurologie und Gastroenterologie befasst. Das Unternehmen vermarktet Gvoke, ein gebrauchsfertiges flüssiges Glukagon zur Behandlung von schwerer Hypoglykämie, und Keveyis, eine Therapie zur Behandlung von hyperkaliämischen, hypokaliämischen und verwandten Varianten der primären periodischen Paralyse, sowie Recorlev, einen Cortisol-Synthesehemmer, der sich zur Behandlung der endogenen Hyperkortisolämie bei erwachsenen Patienten mit Cushing-Syndrom bewährt hat. Darüber hinaus verfügt das Unternehmen über eine Pipeline von Entwicklungsprogrammen zur Erweiterung der vermarkteten Produkte auf neue Indikationen und Verwendungszwecke sowie zur Entwicklung neuer Produkte unter Verwendung der firmeneigenen Formulierungstechnologie-Plattformen XeriSol und XeriJect. Das Unternehmen wurde im Jahr 2005 gegründet und hat seinen Hauptsitz in Chicago, Illinois.